4.8 Article

Dendritic spinopathy in transgenic mice expressing ALS/dementia-linked mutant UBQLN2

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1405741111

Keywords

-

Funding

  1. National Institute of Neurological Disorders and Stroke [NS050641, NS078504, NS070142, NS081474, NS064091, NS009904, NS078287, AG13854]
  2. National Institute on Aging [AG20506]
  3. Les Turner ALS Foundation
  4. Vena E. Schaff ALS Research Fund, a Harold Post Research Professorship
  5. Herbert and Florence C. Wenske Foundation
  6. David C. Asselin MD Memorial Fund
  7. Help America Foundation
  8. George Link, Jr. Foundation
  9. Les Turner ALS Foundation/Herbert C. Wenske Foundation
  10. National Cancer Institute (NCI) [CA060553]
  11. NCI [CA060553]

Ask authors/readers for more resources

Mutations in the gene encoding ubiquilin2 (UBQLN2) cause amyotrophic lateral sclerosis (ALS), frontotemporal type of dementia, or both. However, the molecular mechanisms are unknown. Here, we show that ALS/dementia-linked UBQLN2(P497H) transgenic mice develop neuronal pathology with ubiquilin2/ubiquitin/p62-positive inclusions in the brain, especially in the hippocampus, recapitulating several key pathological features of dementia observed in human patients with UBQLN2 mutations. A major feature of the ubiquilin2-related pathology in these mice, and reminiscent of human disease, is a dendritic spinopathy with protein aggregation in the dendritic spines and an associated decrease in dendritic spine density and synaptic dysfunction. Finally, we show that the protein inclusions in the dendritic spines are composed of several components of the proteasome machinery, including Ub(G76V)-GFP, a representative ubiquitinated protein substrate that is accumulated in the transgenic mice. Our data, therefore, directly link impaired protein degradation to inclusion formation that is associated with synaptic dysfunction and cognitive deficits. These data imply a convergent molecular pathway involving synaptic protein recycling that may also be involved in other neurodegenerative disorders, with implications for development of widely applicable rational therapeutics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available